CD34 and dilated cardiomyopathy: The currently ongoing REMEDIUM trial (repetitive intramyocardial CD34+ cell therapy in dilated cardiomyopathy; NCT 02248532) is evaluating the potential benefits of repetitive transendocardial CD34+ stem cell injections in DCMP patients, and the results are expected to be available by the end of 2017.